Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M403897200 on May 18, 2004

J. Biol. Chem., Vol. 279, Issue 37, 39058-39067, September 10, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/37/39058    most recent
M403897200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bresson, D.
Right arrow Articles by Péraldi-Roux, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bresson, D.
Right arrow Articles by Péraldi-Roux, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Directed Mutagenesis in Region 713-720 of Human Thyroperoxidase Assigns 713KFPED717 Residues as Being Involved in the B Domain of the Discontinuous Immunodominant Region Recognized by Human Autoantibodies*

Damien Bresson{ddagger}§, Martine Pugnière{ddagger}, Françoise Roquet{ddagger}, Sandra A. Rebuffat{ddagger}, Brigitte N-Guyen{ddagger}, Martine Cerutti||, Jin Guo**, Sandra M. McLachlan**, Basil Rapoport**, Valérie Estienne{ddagger}{ddagger}, Jean Ruf{ddagger}{ddagger}, Thierry Chardès||, and Sylvie Péraldi-Roux{ddagger}§§

From the {ddagger}CNRS UMR 5160, Centre de Pharmacologie et Biotechnologie pour la Santé, Faculté de Pharmacie, 15 avenue Charles Flahault, BP 14491, 34093 Montpellier Cedex 5, France, ||INRA-CNRS FRE 2689, Station de Recherche de Pathologie Comparée, 30380 St. Christol-lez-Alès, France, the **Autoimmune Disease Unit, Cedars-Sinai Research Institute and University of California School of Medicine, Los Angeles, California 90048, and {ddagger}{ddagger}U555 INSERM, Faculté de Médecine, Laboratoire de Biochimie Endocrinienne et Métabolique, 13385 Marseille Cedex 5, France

Received for publication, April 7, 2004 , and in revised form, May 17, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Autoantibodies (aAbs) to thyroid peroxidase (TPO), the hallmark of autoimmune thyroid disease (AITD), recognize conformational epitopes restricted to an immunodominant region (IDR), divided into two overlapping domains A and B. Despite numerous efforts aimed at localizing the IDR and identifying aAb-interacting residues on TPO, only two critical amino acids, Lys713 and Tyr772, have been characterized. Precise and complete delineation of the other residues involved in the IDR remains to be defined. By using a recombinant anti-TPO aAb T13, we demonstrated that four regions on TPO are part of the IDR/B; one of them, located between amino acids 713 and 720, is particularly important for the binding of sera from patients suffering from AITD. To precisely define critical residues implicated in the binding of aAb to human TPO, we used directed mutagenesis and expressed the mutants in stably transfected CHO cells. Then we assessed the kinetic parameters involved in the interactions between anti-TPO aAbs and mutants by real-time analysis. We identified (i) the minimal epitope 713-717 recognized by mAb 47 (a reference antibody) and (ii) the amino acids used as contact points for two IDR-specific human monoclonal aAbs TR1.9 (Pro715 and Asp717) and T13 (Lys713, Phe714, Pro715, and Glu716). Using a rational strategy to identify complex epitopes on proteins showing a highly convoluted architecture, this study definitively identifies the amino acids Lys713-Asp717 as being the key residues recognized by IDR/B-specific anti-TPO aAbs in AITD.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Thyroid peroxidase (TPO)1 is an essential membrane-bound enzyme involved in the biosynthesis of iodinated thyroid hormones. As well as thyroglobulin and the thyrotropin receptor, TPO is a major thyroid autoantigen (aAg) targeted by the immune system during autoimmune thyroid diseases (AITD). Human TPO (hTPO) is a 933 amino acid molecule and possesses a highly convoluted three-dimensional structure formed by three distinct modules, respectively, homologous with the myeloperoxidase (MPO), the complement control protein (CCP), and the epidermal growth factor (EGF) (1). This architectural complexity is a strong obstacle for producing high resolution crystals (2, 3), explaining why the only available three-dimensional model has been generated by computer approaches (1). Autoantibodies (aAbs) against hTPO, strongly expressed in patients' sera, are sensitive and specific diagnostic markers for AITD and may play a role in the process leading to thyroid cellular dysfunction and destruction (4-8). More importantly, anti-TPO aAbs have been found to be involved in antigen presentation to autoaggressive T cells (9) and may consequently enhance AITD as previously shown for anti-thyroglobulin aAbs (10). Therefore, a precise delineation of the amino acids constituting the epitopes recognized by human aAbs on TPO would be very helpful for understanding how this aAg is recognized during the onset of AITD, as well as for developing specific immune interventions to prevent or block such pathologies.

A high proportion of anti-TPO aAbs from patients' sera recognizes conformational and discontinuous epitopes, restricted to an immunodominant region (IDR) composed of two overlapping domains called A and B (11-13). Several strategies have been used to localize these domains and, in particular, the critical amino acids involved in aAb interactions: (i) competition for TPO binding between mouse monoclonal antibodies (mAbs) or rabbit polyclonal antisera and human anti-TPO aAb (1, 11, 12, 14), (ii) analysis of human anti-TPO aAb binding to recombinant and/or truncated antigen (15-20), (iii) generation of TPO fragments by enzymatic hydrolysis followed by analysis of their binding to TPO aAb (21), (iv) eukaryotic cell expression of TPO mutants obtained by directed mutagenesis and binding analysis to TPO aAb (22-25), and (v) epitopic footprinting (26).

Interestingly, different studies have pointed out the relationship between region 710 and 722 of hTPO and the B domain of the IDR, as defined with four recombinant human Fab molecules from McLachlan and Rapoport's group (nomenclature used in this article). Chronologically, in 1991, Libert et al. (27) described a linear epitope, called C21, located between amino acid residues 710 and 722, that is able to interact with anti-TPO aAbs in the sera from patients suffering from AITD. During the same year, Finke et al. (28) characterized the mouse mAb 47 produced by Ruf et al. (12), as recognizing a linear determinant in the region 713-721. Further studies, performed by different groups, showed that mAb 47/C21 epitope (i) characterizes in part the B domain of the IDR (12, 13) and (ii) specifically competes with the IDR/B-specific recombinant human monoclonal anti-TPO aAbs TR1.9 and T13 for binding to their cognate antigen (13, 29). These competitions have been explained, firstly, by the fact that Lys713, comprising part of the mAb 47 epitope, was shown to be a contact point for Fab TR1.9 on TPO (26). Secondly, by using the combination of phage-displayed peptide technology followed by sequence alignment between mimotopes and primary sequence of hTPO, we recently localized the discontinuous immunodominant epitope of aAb T13 and found that it is partially composed of region 713-720 of hTPO (29). Importantly, in the same study, we revealed by directed mutagenesis that this region is one major component of the epitopes recognized by human anti-TPO aAbs from patients' sera.

Despite the fact that all these data argue in favor of a critical role of region 713-720 inside the IDR, only one of the residues, Lys713, has been described as being a part of the IDR/B; thus, precise delineation of the critical residues from region 713-720 involved in IDR remains to be elucidated. By a guided mutagenesis study of this region followed by eukaryotic cell expression of each mutant, we identified: (i) the minimal epitope recognized by mAb 47 (amino acids 713-717) and (ii) the amino acids used as contact points for human aAbs TR1.9 (Pro715 and Asp717) and T13 (Lys713, Phe714, Pro715, and Glu716). By using a rational strategy to identify complex epitopes on proteins showing a highly convoluted architecture, the present study definitively assigns the amino acids from TPO region 713-717 as being the key residues recognized by IDR/B-specific anti-TPO aAbs in AITD. These data should be of great importance to rationally design therapeutic peptides able to block undesired autoimmune responses.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
TPO and anti-TPO Autoantibodies—The hTPO, purified (greater than 95% pure) from thyroid glands, was obtained from HyTest Ltd (Turku, Finland). Production and purification of the mouse mAb 47 (12) and the recombinant human Fab TR1.9 (29) were previously described. Anti-TPO mAb 6H7 was purchased from Abcys S.A. (Paris, France). Rabbit polyclonal anti-TPO was prepared in the laboratory by injection of purified hTPO (HyTest Ltd.) in a New Zealand white rabbit, followed by two boosts. Each injection contained ~600 µg of antigen in 1 ml of saline solution and 1 ml of Freund's incomplete adjuvant. The human recombinant aAb T13 was expressed as IgG1 or Fab by using the baculovirus/insect cell system as described (30). Human Fab T13 was purified on a protein G affinity column and the concentration determined by measuring the absorbance at 280 nm, E0.1% of 1.56.

Human aAb T13 (0.5 µg), expressed as Fab or full IgG1, was electrophoresed under non-reducing conditions on 10% SDS-polyacrylamide gel and then transferred to a nitrocellulose membrane (Amersham Biosciences). The Fab T13 expression was checked by Western blotting, using a peroxidase-conjugated anti-human Fab- or Fc-specific Ab (Sigma, dilution 1:1,000) and the ECL detection system (Amersham Biosciences).

The Fab T13 specificity was determined by ELISA. Wells were coated with 1 µg/ml of TPO in 100 mM NaHCO3, pH 9, overnight at 4 °C. Plates were washed with 0.05% Tween 20 in PBS (PBS-T), pH 7.3, and blocked with 2% nonfat dry milk in PBS-T (saturation buffer) for 1 h at 37 °C. After washing, aAb T13, expressed as Fab or the full IgG1 molecule, was incubated with 1% nonfat dry milk in PBS-T (incubation buffer) for 1 h 30 min at 37 °C. After washing, a peroxidase-conjugated anti-human Fab Ab (Sigma, diluted 1:1,000 in the incubation buffer) was added, and the plates were incubated for 1 h at 37 °C. After washing three times, the enzyme activity was detected with a 4 mg/ml 2-phenylenediamine solution containing 0.03% (v/v) hydrogen peroxide in 0.1 M citrate buffer, pH 5.0. After 20 min, the reaction was stopped by adding 50 µl of 2 M H2SO4 to each well, and the resulting absorbance was measured at 490 nm (A490).

Kinetic Parameters of anti-TPO Autoantibody Binding Assessed by BIACORE Analysis—Surface plasmon resonance (SPR) analysis was performed at 25 °C with a 30 µl/min flow rate in HBS-EP (10 mM HEPES buffer, pH 7.4, 3 mM EDTA, 0.005% Biacore surfactant P20, 150 mM NaCl), using a BIACORE 3000 instrument (Biacore AB, Uppsala, Sweden). To measure the association and dissociation rate constants (ka and kd, respectively), and the dissociation equilibrium constant (KD = kd/ka) for the binding of mAb 47, IgG1 or Fab T13, and Fab TR1.9, human TPO was covalently immobilized at 1500 RU on the flow cell of a CM5 sensorchip by the amine coupling kit provided by the manufacturer. A second flow cell was subjected to the same chemical treatment without the protein and used as reference. Five concentrations of anti-TPO Ab were injected during 180 s over the two flow cells, followed by a dissociation step of 400 s and a regeneration step (10 µl of 40 mM HCl) between each concentration analysis. All the sensorgrams were corrected by subtracting the signal from the reference flow cell and were globally fitted to a 1:1 Langmuir binding isotherm using BIAevaluation version 3.2 software. Irrelevant mAb and Fab were used as analyte without giving any binding signal. Experiments at different flow rates showed an absence of mass transport and rebinding effects.

Peptide Synthesis and Immunoassay on Cellulose Membrane-bound Peptides—The general protocol for Spot parallel peptide synthesis was described previously (31). A set of 14-mer synthetic peptides corresponding to the region 709-722 of hTPO and its fourteen alanine analogs were synthesized by the Spot method. The membrane-bound peptides were probed by incubation of 2 µg/ml of mAb 47, Fabs T13, or TR1.9. Antibody binding was detected by using an alkaline phosphatase-conjugated anti-mouse Ig (Sigma, diluted 1:1,000), followed by addition of the phosphatase substrate 5-bromo-4-chloro-3-indoyl phosphate and thiazolyl blue tetrazolium (Sigma), which gives a blue precipitate on peptides having bound the antibody. The membrane was re-used after a regeneration cycle. The intensity of the spots was evaluated with the ScionImage software.

Blocking ELISA Experiments—The wells were coated with 1 µg/ml TPO in 100 mM NaHCO3, pH 9.6, overnight at 4 °C. Plates were washed and blocked with saturation buffer for 1 h at 37 °C. After washing three times, mouse mAb 47 or 6H7 was incubated at two concentrations (50 and 5 µg/ml) in incubation buffer for 2 h at 37 °C. Washing was performed and then human Fab T13 or TR1.9 was incubated at a concentration giving an A490 of 1.5. After 1 h at 37 °C and washing, a horse-radish peroxidase-conjugated anti-human (Fab')2, diluted 1:8,000 (Sigma), was used to detect the binding of human Fab on TPO by incubation 1 h at 37 °C. Washing (3x) was performed, and then the reactivity was revealed as described above. The percent inhibition was calculated by comparing the binding of human Fab with or without inhibitor.

Guided Mutagenesis and Stable Expression of Wild-type and Mutated TPO Complementary DNA—The full-length wild type (wt) and mutated TPO in the region 713-720 (fully mutated TPO713-720) were previously cloned in the pcDNA5/FRT expression vector from the Flp-InTM system (29). The eight amino acids in the region 713-720 were replaced by leucine, and a triple mutant was constructed by replacing the residues Lys713, Pro715, and Glu716 by residues Ser713 and Arg716, derived from the myeloperoxidase sequence, and Ala715. All mutants were constructed by overlap extension PCR as described previously (32). The final PCR products were cloned into the full-length TPO cDNA by using the unique restriction endonuclease sites ClaI and EcoNI. All sequences were verified by the dideoxynucleotide termination method (33). Then, the Flp-InTM system was used to generate isogenic stable Chinese hamster ovary (CHO) cell lines expressing wt or mutated TPO as we previously described (29). Cloning and expression of TPO fully mutated in the regions 713-720 (TPO713-720) or 506-514 (TPO506-514) were previously described (29).

Flow Cytometry Analysis of Wild-type or Mutated TPO Expressed on the Surface of Stably Transfected CHO Cells—Stably transfected CHO cells were scraped, rinsed, and pelleted (5 min, 900 rpm, 4 °C) in PBS supplemented with 2% heat-inactivated fetal calf serum (FACS buffer). The cells were resuspended and incubated with 200 µl of buffer containing 5 µg/ml of a rabbit polyclonal anti-TPO Ab or 2 µg/ml of mAb 47 for 45 min at 4 °C. The cells were washed three times and incubated in 200 µl of FACS buffer with 10 µg/ml of fluorescein-conjugated anti-rabbit (Sigma) or anti-mouse IgG (Rockland, Gilbertsville, PA) for 45 min at 4 °C in the dark. As control, the cells were incubated with second Ab alone. After washing three times with FACS buffer, the cells were analyzed (10,000 events) on an EPICS cytofluorometer (Beckman-Coulter, Fullerton, CA).

Membrane Protein Extraction from CHO Cells—Stably transfected or wt CHO cells were washed three times with PBS and scraped at 4 °C. Membrane protein extraction was performed as previously described (29). After centrifugation at 1,000 rpm for 5 min at 4 °C, membrane proteins were solubilized by adding 500 µl of cold lysis buffer (PBS containing 0.5% Triton X-114 and a protease inhibitor mixture tablet/10 ml of lysis buffer (Roche Applied Science), maintained at 4 °C) per 106 cells, and incubated for 30 min on ice (mixed by vortexing every 10 min). After centrifugation at 800 rpm for 8 min at 4 °C, the supernatants containing the membrane proteins were recovered and incubated for 5 min at 33 °C to allow the separation of the detergent from the aqueous phase. After centrifugation at 800 rpm for 8 min at 22 °C, the upper aqueous phase, containing soluble TPO, was removed and concentrated to ~10 mg/ml using an Ultrafree®-4 Centrifugal Filter Unit (Millipore Corp., Bedford, MA). All protein concentrations were evaluated by the BCA protein assay reagent (Pierce).

Binding of Solubilized Membrane Proteins Containing Wild-type or Mutated TPO to Human Fab Assessed by BIACORE Analysis—Human Fab T13 or TR1.9 were covalently immobilized at 9,600 RU or 3,600 RU, respectively, on flow cells 2 and 3, respectively, of a CM5 sensorchip-activated surface with EDC/NHS (amine coupling kit from Biacore AB). Flow cell 1 was used as the reference control surface. Each solubilized membrane protein extract, containing wt or mutated TPO, was diluted in HBS-EP buffer to the same final total protein concentration (1 mg/ml) and loaded onto flow cells 1, 2, and 3 in a single injection of 90 µl. After dissociation (400 s), eluent buffer (HBS-EP) at a flow rate of 30 µl/min was injected, and then the flow cell surfaces were regenerated with 10 µl of 5 mM HCl. To control the binding stability of the immobilized Fab T13 and TR1.9, each membrane protein analysis was preceded and followed by an injection of solubilized membrane protein extract containing wt TPO under the same conditions. As a negative control, a preparation of membrane proteins obtained from non-transfected CHO cells was diluted to the same final protein concentration and injected over the flow cells. Three independent experiments were performed.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Production, Functionality Analysis, and Kinetic Binding Parameters of Human Fab T13—The anti-TPO aAb T13, previously produced as full IgG1 (30), was cloned and expressed as human Fab by using the baculovirus/insect cell system as described (34). Human Fab T13 was purified by protein-G affinity chromatography (purity greater than 95%, data not shown) and then analyzed on 10% SDS-PAGE (Fig. 1A). We observed a 50-kDa band corresponding to human Fab T13, only detectable by the peroxidase-conjugated anti-human Fab Ab but not by the peroxidase-conjugated anti-human Fc-specific Ab (Fig. 1A, lane 3 versus lane 1). Human T13 expressed as full IgG1 could be detected by both secondary Abs (Fig. 1A, lane 2 versus lane 4). Approximately 0.5 mg of purified Fab T13 was obtained per liter of Sf9 insect cell culture supernatant. The functionality of Fab T13 was checked by ELISA. The results clearly show that human Fab T13 was able to bind to hTPO, in a dose-dependent manner, as was the full IgG1 T13 (Fig. 1B).



View larger version (18K):
[in this window]
[in a new window]
  		FIG. 1.
Functional analysis of human Fab T13. Expression and functional analyses were performed as described under "Experimental Procedures." A, each sample (0.5 µg) was charged under non-reducing conditions on a 10% SDS-polyacrylamide gel and analyzed by Western blotting. Lanes 1 and 3, purified human Fab T13. Lanes 2 and 4, purified human IgG1 T13. After transfer, proteins in lanes 1 and 2 were detected with a peroxidase-conjugated anti-human Fc specific Ab, whereas those in lanes 3 and 4 were detected with a peroxidase-conjugated anti-human Fab. B, the functionality of aAb T13 was analyzed by ELISA. The binding of human aAb T13, expressed as Fab or full IgG1, on hTPO is shown.

 
Affinity Measurements of Human Fabs T13, TR1.9, and mAb 47 Binding to TPO—By using BIACORE technology (Fig. 2, A-D), we determined the binding kinetics for the interaction between Fab T13, full IgG1 T13, Fab TR1.9, or mAb 47 and hTPO immobilized on the sensorchip. The kinetic parameters of aAb T13 binding, produced as Fab (Fig. 2A) or full IgG1 (Fig. 2B), were measured after separate injections of five different concentrations of purified aAb on TPO. We found affinities (KD) for IgG1 and Fab T13 of 0.19 ± 0.01 nM and 0.80 ± 0.02 nM, respectively, using the same global fitting model, with a higher association rate constant for aAb T13 expressed as whole IgG1 versus Fab and quite similar dissociation rate constants (Fig. 2E). The difference observed between the association rate constants is probably due to a stronger avidity of the full IgG1 (two paratopes) in comparison with the Fab T13 (one paratope). In a previous study (30), we reported an affinity value for aAb T13 immobilized by an anti-human IgG Fc antibody similar to that of Fab T13, avidity effects being avoided by this protocol. These data confirm the high affinities of human Fabs T13 and TR1.9 for TPO (KD = 0.80 ± 0.02 nM and 0.05 ± 0.01 nM, respectively) (26). The stronger affinity for Fab TR1.9 could be explained by the remarkable association rate constant of human Fab TR1.9 (ka = 64.10 ± 0.02 x 105 M-1 s-1) (Fig. 2E). In previous studies, using Scatchard analysis, the affinity of mAb 47 could not be calculated, probably because this mAb binds with a low affinity to TPO (KD less than 10-7 M) (13). In our experiment (Fig. 2E), this mAb strongly interacted with TPO immobilized on the BIACORE sensor chip and showed high affinity binding with KD = 0.11 ± 0.001 nM, which is similar to that obtained with human Fabs T13 and TR1.9 using the same binding protocol. One explanation for such a difference in the mAb 47 affinity value could be that the Scatchard analysis was performed with soluble and highly convoluted TPO, whereas real-time analysis used a covalently immobilized TPO.



View larger version (30K):
[in this window]
[in a new window]
  		FIG. 2.
BIACORE affinity measurements of human Fabs T13 and TR1.9 and mAb 47 binding to human TPO. Different concentrations of anti-TPO Ab in HBS-EP (ranging from 0.31 to 5 µg/ml for Fab T13 (A), 0.07 to 2.5 µg/ml for mAb T13 (B), 0.03 to 0.15 µg/ml for Fab TR1.9 (C), and 0.37 to 10 µg/ml for mAb 47 (D) were injected during 180 s over the TPO-immobilized flow cell. Kinetic data for the interactions of hTPO with each anti-TPO Ab are indicated (E). Each kinetic experiment was repeated twice.

 
Evidence That Human Fabs T13 and TR1.9, as Well as mAb 47, Interact with the Region 713-721 of hTPO—Mouse mAb 47 has been used as reference to describe the B domain of the IDR and often in competition with human anti-TPO aAb (13, 15, 29, 35). Previous data localized the mAb 47 epitope between amino acids 713 and 721 by using TPO protein fragments expressed in an hTPO cDNA sub-library (28). We performed a blocking ELISA experiment to assess the ability of Fabs T13 and TR1.9 to interact with region 713-721 of hTPO recognized by mAb 47. The binding of the human Fabs T13 and TR1.9 to hTPO was inhibited in a dose-dependent manner by mAb 47 but not by the control anti-TPO mAb 6H7 (Fig. 3). These data indicate that the mAb 47 and both human Fabs, but not the mAb 6H7, bound in close proximity on the hTPO molecule causing steric hindrance.



View larger version (16K):
[in this window]
[in a new window]
  		FIG. 3.
mAb 47 inhibits the binding of human Fabs T13 and TR1.9 to human TPO. Competitive ELISA experiments were performed with mouse mAb 47 or 6H7 (control) as competitor for the binding of human Fab T13 and Fab TR1.9 to TPO (see "Experimental Procedures"). The results are expressed as mean ± S.D. of triplicate values.

 
Spot Peptide Analysis Identifies Residues 713-717 Recognized by mAb 47 but Fails to Define Fabs T13- and TR1.9-interacting Residues—Using TPO protein fragments expressed in an hTPO cDNA sub-library, the mAb 47 epitope was found to be restricted to region 713-721 (28). Spot analysis of 20-mer overlapping peptides frameshifted by five residues, covering the entire sequence of the MPO- and CCP-like domains of TPO, revealed that peptides from region 701-732 with the motif 713KFPEDFES720 are recognized by mAb 47 (data not shown). To determine the critical amino acids involved in the recognition of mAb 47 to TPO, 15 peptides corresponding to the amino acid sequence of region 709-722 of hTPO (wt sequence and 14 peptides resulting from an alanine scan) were synthesized on a cellulose membrane. As shown in Fig. 4 mAb 47 strongly reacted with the wt 709-722 peptide, whereas the alanine mutations in positions Lys713, Pro715, and Glu716 totally abolished the binding of mAb 47 to the mutated peptides. Furthermore, the mutation of residues Phe714 and Asp717 partially decreased (inhibition of 11 and 24%, respectively) the binding of mAb 47 to the peptides as determined by comparison of spot intensities indicated on the left side of Fig. 4. Taken together, these results indicate that the minimal epitope recognized by mAb 47 is assigned to residues between amino acids 713 and 717, with the motifs Lys713, Pro715, and Glu716 essential for antibody binding. On the other hand, no reactivity with the wt peptide was observed with Fabs T13 or TR1.9 by using the spot technology (data not shown), confirming that interaction between TPO and these aAb fragments is more complex than that between mAb 47 and its linear epitope.



View larger version (52K):
[in this window]
[in a new window]
  		FIG. 4.
Determination of mAb 47 minimal epitope by the Spot technology. The minimal epitope of mAb 47 was determined as described under "Experimental Procedures." The wild type 709-722 amino acid sequence and a series of alanine analogs of this region were prepared and tested according to the Spot method. The mAb 47 reactivity was measured by using an alkaline phosphatase-conjugated anti-mouse Ig followed by addition of a phosphatase substrate (5-bromo-4-chloro-3-indoyl phosphatase and thiazolyl blue tetrazolium bromide, Sigma); the product of the reaction gives a blue precipitate on peptides having bound the antibody. Signal intensities depend on the quantity of mAb bound to each Spot. The color intensity of each spot was determined using ScionImage software and is indicated on the left-hand side of the figure.

 
Flow Cytometry Analysis of CHO Cells Expressing Full-length TPO Mutants Confirms That the 713-717 Region Corresponds to the Minimal Epitope of mAb 47 but Still Fails to Identify T13- and TR1.9-interacting Residues—Using the Flp-InTM system (29), we produced eight single amino acid mutants between positions 713 and 720 of hTPO and a mutant called TPOKPE-SAR with a triple mutation, where residues Lys713, Pro715, and Glu716 (described above as essential for the binding of mAb 47) were replaced by residues Ser713, Ala715, and Arg716. To compare the TPO expression levels obtained for each mutant on the surface of stably transfected CHO cells, flow cytometry experiments were performed with a rabbit polyclonal anti-TPO. As indicated in Fig. 5A, similar cytometry patterns showing strong binding of the rabbit polyclonal anti-TPO serum were obtained for all mutant TPO-transfected CHO cells in comparison with wt TPO-transfected cells, whereas no binding was observed with non-transfected cells. On the contrary, when mAb 47 was tested by flow cytometry, its binding to CHO cells transfected with mutants TPOK713L, TPOF714L, TPOP715L, TPOE716L, TPOD717L, and to mutant TPOKPE-SAR was totally abolished (Fig. 5B). No specific signal was observed either with the non-transfected cells. These data definitively confirm that the minimal epitope of mAb 47 lies between Lys713 and Asp717 and demonstrate the functional role of these amino acids substitutions in region 713-720 of hTPO.



View larger version (45K):
[in this window]
[in a new window]
  		FIG. 5.
Flow cytometry analysis of the binding of rabbit polyclonal Ab and murine mAb 47 to wild-type or mutated TPO expressed on the surface of stably transfected CHO cells. A, rabbit polyclonal anti-TPO Ab was incubated with CHO cells expressing wt or mutated TPO (control mutant between amino acids 506 and 514 (27), triple mutant TPOKPE-SAR and site-specific mutations between amino acid residues 713 and 720) (see "Experimental Procedures"). B, binding of mAb 47 on CHO cells expressing wt or mutated TPO was analyzed. Non-transfected CHO cells were used as control. The mean fluorescence intensities of the signals for each panel are shown in parentheses.

 
In an attempt to demonstrate that region 713-720 of hTPO contains amino acids involved in the binding of the human Fabs T13 and TR1.9, we incubated these Fabs with CHO cells expressing wt or mutated TPO. Neither of the antibody fragments was able to bind to control CHO cells, whereas human Fabs T13 and TR1.9 were able to bind to CHO cells expressing wt or control mutated TPO506-514 with a similar signal, and to a lesser extent, to CHO cells expressing fully mutated TPO713-720 or the triple amino acid mutant TPOKPE-SAR (data not shown). By flow cytometry, no significant difference was observed between CHO cells expressing wt or a point-mutated TPO, whatever the Fab concentration tested (data not shown).

BIACORE Analysis Demonstrates That Part of the IDR Recognized by Human Autoantibodies T13 and TR1.9 Lies between Residues Lys713 and Asp717—We decided to use the BIACORE technology to measure the kinetic parameters of the interaction between human Fabs and TPO. Membrane protein was extracted from non- or stably transfected CHO cells, expressing wt or mutated TPO. Each membrane protein preparation was injected over the human Fabs T13 or TR1.9 immobilized on the flow cell of a CM5 sensorchip (BIACORE). No specific binding was observed with the proteins extracted from the non-transfected CHO cells, whereas the proteins obtained from CHO cells expressing wt TPO or TPO713-720 showed significant binding to each Fab (Fig. 6, A and B). The other mutants bound at a level between 50 and 200 RU on each Fabs. Because of the difficulty to measure the TPO concentration in the membrane extracts, we decided to analyze the dissociation rate (kd), which is independent of the analyte concentration (wt or mutated TPO in the present case). The complete mutation in the region 713-720 of hTPO (TPO713-720) affected the binding to Fabs T13 and TR1.9 by causing an increase in the dissociation rate in comparison with wt TPO (TPOwt) (Fig. 6, C and D). Single amino acid mutants showed various dissociation patterns (Fig. 6, C and D). In particular, the dissociation curves corresponding to the binding of Fab TR1.9 to TPOP715L and TPOD717L cell extracts (Fig. 6C) and of Fab T13 to TPOKPE-SAR, TPOF714L, and TPOP715L cell extracts (Fig. 6D) were markedly increased.



View larger version (36K):
[in this window]
[in a new window]
  		FIG. 6.
Several amino acids in region 713-720 contribute to the binding of human Fab T13 and Fab TR1.9 on human TPO as evidenced by real-time analysis. Solubilized CHO membrane proteins containing wt or mutated TPO were diluted to obtain the same final total protein concentration and separately injected over Fab T13 or Fab TR1.9 previously immobilized on the flow cell of a CM5 sensorchip (BIACORE 3000 technology). Representative sensorgrams of the binding of CHO membrane protein extracts containing wt TPO or fully mutated TPO713-720 versus a non-transfected cell membrane protein preparation (Mock) to Fab TR1.9 (A) and Fab T13 (B) are respectively displayed. Dissociation curves of the binding of the various mutant preparations to Fab TR1.9 (C) and Fab T13 (D) were fitted, and the dissociation rate constants (kd) measured by using BIAevaluation version 3.2 software. These data are expressed in the histogram (E), which displays the ratio R of ({Delta}kd mutant/{Delta}kd713-720) as a percentage, where {Delta}kd mutant = (kd TPOmut - kd TPOwt) and {Delta}kd713-720 = (kd TPO713-720 - kd TPOwt). The solubilized membrane extract containing wt TPO was injected twice, before and after the mutants, to control the stability of each human Fab. The data were verified in three independent experiments with three different protein extractions.

 
To compare the mutants, we assessed the dissociation rates obtained after injecting the membrane protein extracts containing wt or mutated TPO over the immobilized Fab T13 or TR1.9. The kd variation ({Delta}kd) values were calculated as the difference between the dissociation rate of fully mutated TPO713-720 or point mutated TPO (TPOmut) and wt TPO. The dissociation rates observed with the wt TPO protein preparation were 8.22 ± 0.23 x 10-4 s-1 on immobilized T13 and 0.75 ± 0.01 x 10-4 s-1 on immobilized TR1.9. The dissociation rates observed with TPO713-720 preparation were 16.5 ± 0.3 x 10-4 s-1 on immobilized T13 and 4.58 ± 0.04 x 10-4 s-1 on immobilized TR1.9. The controls (Fig. 6E), mutations in region 506-514 of hTPO (TPO506-514), did not increase the dissociation rate of human Fabs. Interestingly, several site-specific mutations directly increased the dissociation rates measured for Fabs T13 and TR1.9 ({Delta}kdmut/{Delta}kd713-720 greater than 10%). Residue Pro715 strongly contributed to the binding of Fab T13 to region 713-720 of hTPO ({Delta}kdP715/{Delta}kd713-720 = 46.8 ± 2.2%), whereas three other residues, Lys713, Phe714, and Glu716, which had a ratio between 12% and 14.4% were found to be involved to a lesser extent in Fab T13-TPO interaction. On the other hand, residue Asp717 was found to be the main contributor to Fab TR1.9 binding to region 713-720 ({Delta}kdD717/{Delta}kd713-720 = 65.4 ± 1.8%, Fig. 6E), whereas Pro715 residue participated to a lesser extent to the binding of Fab TR1.9 to hTPO, with a ratio of 26.9 ± 0.9% (Fig. 6E).

A three-dimensional model of the MPO-like domain of hTPO (Fig. 7) shows that residues Lys713, Pro715, and Glu716 protrude outside the molecule, whereas residues Phe714 and Asp717 are buried inside TPO. As shown in Fig. 7, the IDR/B architecture in region 713-720, recognized by human aAbs, is mainly formed by a group of amino acids composed of the aromatic Phe714 and the negatively charged Asp717 residues and also a protruding amino acid cluster, comprised of the Pro715 residue and the charged residues Lys713 and Glu716 whose side chains are accessible to the solvent.



View larger version (69K):
[in this window]
[in a new window]
  		FIG. 7.
Modeled architecture of IDR-B from region 713-717 recognized by human recombinant autoantibodies T13 and TR1.9. Ribbon diagram of the structure of hTPO showing the MPO-like domain is reproduced with permission (1). Localization of the epitope 713KFPED717 is highlighted by space-filling, with residues Lys713 in red, Phe714 in cyan, Pro715 in yellow, Glu716 in green, and Asp717 in magenta. The model was adjusted using the Swiss-PDB viewer 3.7b2 freeware available at www.expasy.ch/spdbv.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
In this study we demonstrated, by using wt or mutated TPO extracted from stably transfected CHO cells followed by a realtime analysis (BIACORE technology), that amino acids Lys713 to Asp717 correspond to one major part of the IDR/B recognized by human anti-TPO aAb and represent the minimal epitope for mAb 47, described as a reference murine antibody for the B domain of the TPO IDR.

Numerous studies published during the past two decades have shown that the IDR recognized by human aAb on the surface of hTPO is highly discontinuous (28, 36-38). Indeed hTPO presents a highly convoluted architecture composed of three distinct modules designated as MPO-, CCP-, and EGF-like domains (1). This characteristic makes the identification of amino acids taking part in the IDR extremely difficult. Many unfruitful efforts using the directed mutagenesis approach have been made to determine the amino acid residues in contact with human anti-TPO aAb (1, 23-25). Two recent studies showed that the (i) tyrosine residue in position 772 belongs to the IDR (22) and (ii) regions 353-363, 377-386, 713-720, and 766-775 of hTPO form an immunodominant binding surface for human anti-TPO aAb (29). Studies of the 766-775 region of hTPO, which contains Tyr772, took advantage of the fact that the CCP- and EGF-like domains of hTPO can be expressed together by eukaryotic cells, in the absence of the MPO-like domain (15, 39). Since, the major part of the IDR on hTPO is located in the MPO-like domain (29, 40), we decided to stably express on the CHO cell surface the full-length wt or mutated hTPO by combining two technological approaches (directed mutagenesis followed by the Flp-InTM expression system). Flow cytometry analysis performed with these transfected CHO cells clearly showed that the minimal epitope to which mAb 47 binds is localized between amino acids Lys713 and Asp717. This cellular approach confirmed the data obtained by the Spot technique for the residues Lys713, Pro715, and Glu716 and showed that the positions Phe714 and Asp717 on TPO were also, but to a lesser extent, implicated in the binding of mAb 47. Such subtle differences could be explained by the high peptide density synthesized on cellulose membranes by the Spot method (~0.2 µM of peptide per spot), favoring mAb 47 avidity.

Controversial studies assigned the mAb47/C21 epitope (amino acid residues 713-721) sometimes as part of the IDR (12, 26, 35) and sometimes not (11, 25, 41). After several years of questioning, all recent data emphasize the importance of region 713-721 for the binding of the human anti-TPO aAb (26, 29, 40). By direct footprinting, Guo et al. (26) identified the Lys713 residue as a contact point for human monoclonal aAb TR1.9, which recognizes a part of the IDR/B. Surprisingly, in our present study, replacement of Lys713 by Leu713 did not increase the dissociation rate of Fab TR1.9. Three explanations can be given. (i) Lys713 is directly involved in the association rate and does not affect the TR1.9 dissociation rate we measured in our BIACORE experiment. (ii) The protocol used for real-time analysis used in this study is not suitable for highlighting a direct influence of Lys713 on the binding of TR1.9 to hTPO. (iii) More drastic mutation, namely, shortening the amino acid side chain length (i.e. replacement of Lys by a Val or an Ala residue) is probably necessary to affect TR1.9 antibody binding. Moreover, an epitope on a large protein involves ~20 contact amino acid residues. Mutation of only one antigenic residue (such as Lys713) may therefore, have only a minor effect on the binding affinity of the Fabs, as we indeed observed with TR1.9. Consistent with our present finding, Guo et al. (26) showed that mutation of a more extensive region (residues 713-720) only partially affected the binding of TR1.9. Therefore, although Lys713 is a contact residue for TR1.9, our present data indicate that it contributes very little, if at all, to TR1.9 affinity.

Single amino acid substitutions in region 713-720 of hTPO moderately reduced human aAb affinity and did not decrease the binding of the human aAbs to hTPO by flow cytometry; such results depend, however, on the antibody used. We must keep in mind that (i) the influence of an individual amino acid on the interaction with an anti-TPO antibody can be slightly different and sometimes modest for a given region, even if all these antibodies are characterized as being able to bind this region, as previously described (26, 28, 29), and (ii) human anti-TPO aAb such as T13 and TR1.9 recognize a discontinuous epitope involving multiple regions on hTPO, in contrast to mAb 47, which is directed against a linear sequence 713-717. Therefore, we devised a new protocol, combining membrane protein extraction from eukaryotic cells with real-time analysis, to assess the influence of the kinetic parameters on the interaction between human aAbs and their cognate antigen expressed on CHO cells. The TPO concentration, in membrane protein extracts, is very difficult to estimate. For this reason, we focused on the dissociation rate constant (kd), which is independent of the analyte concentration (the wt or mutated TPO in our study) but represents the interaction force between two proteins. Our results highlight the fact that at least four amino acids (Lys713, Phe714, Pro715, and Glu716) for Fab T13 and two (Pro715, Asp717) for Fab TR1.9 contribute to the binding of these human aAbs to region 713-720 of hTPO. The amino acid residue Pro715 is the only amino acid whose presence increases the dissociation rate for both Fabs T13 and TR1.9. Due to the importance of this amino acid in the folding of proteins, we cannot formally exclude the fact that a mutation in this position would induce a slight change in the three-dimensional structure of region 713-720 of hTPO, thus explaining its effects on the binding of aAbs T13 and TR1.9 to TPO. We propose that residue Pro715 could play a role in structuring the antigenic loop but without directly interacting with aAbs T13 and TR1.9.

Our results, shown in Fig. 3, are in accordance with the fact that mAb 47 strongly inhibits the binding of Fab T13 to hTPO but to a lesser extent than the binding of Fab TR1.9 to hTPO. Indeed, region 713-720, constituting one part of the Fab T13 discontinuous epitope, possesses four amino acids common to the mAb 47 epitope, whereas the epitopes recognized by mAb 47 and Fab TR1.9 have only three residues in common (26 and the present study). This observation is perhaps a clue to understanding why it has been so difficult up to now to determine whether, by using the human aAb TR1.9, the region 713-720 of hTPO is part of the IDR or not (11, 25, 26).

Recently, in an attempt to identify the TPO immunodominant epitope, several mimotopes that mimic the discontinuous epitope recognized by the T13 aAb were selected (29). These mimitopes were grouped into three families on the basis of their sequence homology. Four T13-specific mimotopes of family 1, obtained by biopanning on TPO from four phage-displayed libraries, largely matched with region 713-721 of TPO (29) and carry most of the residues found to interact with Fab T13, Fab TR1.9 or mAb 47 in the present study. Of interest, the motif LXPEXD (where X represents any amino acid), identified by alanine scanning as bearing critical residues for family 1-mimotope binding to T13 (29), mimics the Pro715 and Glu716 major anchor residues for human Fab T13; amino acids Pro715 and Asp717, characterized as contact points for human TR1.9 Fab; and Pro715, Glu716, and Asp717, essential residues for IDR/B-specific mAb 47 (Fig. 4). Two other residues, Lys713 and Phe714, were found to interact with Fab T13 by real-time analysis and with mAb 47 by flow cytometry studies on TPO-mutated CHO cells in the present study, whereas only amino acid Lys713 was identified as a TR1.9-interacting residue by footprinting (26). These two latter residues do not belong to the mimotope's critical motif LXPEXD (29). However, a precise observation of two out of the four family 1 mimotopes (KLLPEDDESRTYHTV and KLFPEEDEMRTETQR), which match in the region 713-720 (29), allowed us to identify a lysine residue in both mimotopes and a phenylalanine residue in the second mimotope just before the proline, as expected given the wt sequence of hTPO. Taken together, these observations reinforce our data demonstrating that residues Lys713-Asp717 correspond to a major part of the IDR/B recognized by human anti-TPO aAb.

Finally, these data further emphasize the importance of region Lys713-Asp717 for TPO recognition by human aAbs. Indeed, we previously observed that the binding of human anti-TPO aAbs from the serum of patients suffering from AITD is strongly affected when region 713-720 is fully mutated (29), suggesting that peptides encompassing amino acids 713-720 are predominantly presented to the immune system during onset of AITD. The resulting anti-TPO aAb response could be even more restricted and directed against amino acids in region 713-717 of hTPO (present data).

It is now strongly believed that viral infections can trigger autoimmune diseases when they occur in predisposed patients, either by inducing virus-mediated cell damage of target organs or by molecular mimicry, thus activating an immune response not only against a viral peptide but also against the aAg encompassing the same amino acid sequence (42-46). For example, it has been shown that the primary sequence of the 65-kDa isoform of glutamic acid decarboxylase (GAD65) contains a PEVKEK motif which is (i) part of the discontinuous epitope recognized by a well-described human-derived mAb MICA3 and (ii) also present in the primary sequence of protein 2C from Coxsackie B4 virus (CBV) (47). Such results favor the hypothesis, now well documented (48), that CBV infection may trigger type 1 diabetes by the process of viral mimicry with subsequent cross-reactivity with a critical epitope of GAD65. Importantly, by performing a BLAST sequence alignment between the motif 713KFPED717, which we found to be a critical epitope, and all virus sequences in the database, we identified one perfect sequence homology with the amino acids 450-454 of human metapneumovirus (hMPV), a single-stranded RNA virus, which causes lower respiratory infection disease in children (49). Thus, a relationship between hMPV infection and AITD should be investigated.

By using competitive experiments with rabbit anti-peptide antibodies (1, 12), residues 599-617, located on the opposite face of the TPO molecule, compared with the 713KFPED717 epitope we characterized, were identified as being part of the IDR. This observation raises another question: Does region 599-617, together with region 713-717 and regions 353-363, 377-386, and 766-775 of hTPO, belong to the same immunodominant binding surface or does it clearly assign another domain on the IDR (the IDR-A)? Each of these hypotheses is probably valid because of (i) the ability of hTPO to dimerize (50) and (ii) the high flexibility of the hinge regions between the MPO-, CCP- and EGF-like domains of hTPO (22, 29, 40), leading to a spatial readjustment of the IDR.

In conclusion, by using a new approach combining extraction of membrane protein from eukaryotic cells and real-time interaction analysis, we provide the complete identification of residues 713-717 of hTPO as being a major component of the IDR/B recognized by human anti-TPO aAbs. Identification of the amino acids comprising the IDR is essential for our understanding of how TPO is recognized as an aAg by the immune system during the onset of AITD. Therapeutically, a better knowledge of the amino acids in contact with anti-TPO aAbs would certainly be useful in designing highly potent peptides able to delude and deviate the humoral response leading to thyroid destruction. Even if the co-crystallization between a human monoclonal anti-TPO aAb and its cognate antigen remains the only way to definitely identify all the interacting amino acids, our study provides a rational strategy for identifying complex epitopes of a given protein showing a highly convoluted architecture. Our present data definitively assign key residues from the TPO region 713-717 of the IDR/B recognized by pathological aAb in AITD.


   FOOTNOTES
 
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

§ Recipient of a fellowship from the CNRS and the Région Languedoc-Roussillon. Current address: La Jolla Institute for Allergy and Immunology, Dept. of Developmental Immunology-3, 10355 Science Center Drive, San Diego, CA 92121. Back

Both authors contributed equally to this work. Back

§§ To whom correspondence should be addressed: CNRS UMR 5160, Centre de Pharmacologie et Biotechnologie pour la Santé, 15 avenue Charles Flahault, BP 14491, 34093 Montpellier, Cedex 5, France. Tel.: 33-467-548-604; Fax: 33-467-548-610; E-mail: sylvie.roux{at}ibph.pharma.univ-montp1.fr.

1 The abbreviations used are: TPO, thyroid peroxidase; aAg, autoantigen; AITD, autoimmune thyroid diseases; MPO, myeloperoxidase; CCP, complement control protein; EGF, epidermal growth factor; aAb, autoantibody; IDR, immunodominant region; CHO, chinese hamster ovary; wt, wild type; ELISA, enzyme-linked immunosorbent assay; PBS, phosphate-buffered saline; RU, resonance unit; mAb, monoclonal antibody; FACS, fluorescent-activated cell sorting. Back


   ACKNOWLEDGMENTS
 
We thank Dr. S. L. Salhi for carefully reading and editing the manuscript. We are also grateful to Dr. S. Villard for the Spot synthesis and J. Hoebeke for helpful discussions. We acknowledge A. Ozil for excellent technical assistance with the baculovirus expression. We also thank Drs. B. J. Sutton, P. Hobby, and J. P. Banga for permission to use the three-dimensional model of TPO.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Hobby, P., Gardas, A., Radomski, R., McGregor, A. M., Banga, J. P., and Sutton, B. J. (2000) Endocrinology 141, 2018-2026[Abstract/Free Full Text]
  2. Hendry, E., Taylor, G., Ziemnicka, K., Grennan Jones, F., Furmaniak, J., and Rees Smith, B. (1999) J. Endocrinol. 160, R13-R15[Abstract]
  3. Gardas, A., Sohi, M. K., Sutton, B. J., McGregor, A. M., and Banga, J. P. (1997) Biochem. Biophys. Res. Commun. 234, 366-370[CrossRef][Medline] [Order article via Infotrieve]
  4. Chiovato, L., Bassi, P., Santini, F., Mammoli, C., Lapi, P., Carayon, P., and Pinchera, A. (1993) J. Clin. Endocrinol. Metab. 77, 1700-1705[Abstract]
  5. Parkes, A. B., Othman, S., Hall, R., John, R., Richards, C. J., and Lazarus, J. H. (1994) J. Clin. Endocrinol. Metab. 79, 395-400[Abstract]
  6. Rodien, P., Madec, A. M., Ruf, J., Rajas, F., Bornet, H., Carayon, P., and Orgiazzi, J. (1996) J. Clin. Endocrinol. Metab. 81, 2595-2600[Abstract]
  7. Metcalfe, R. A., Oh, Y. S., Stroud, C., Arnold, K., and Weetman, A. P. (1997) Autoimmunity 25, 65-72[Medline] [Order article via Infotrieve]
  8. Guo, J., Jaume, J. C., Rapoport, B., and McLachlan, S. M. (1997) J. Clin. Endocrinol. Metab. 82, 925-931[Abstract/Free Full Text]
  9. Guo, J., Wang, B., Rapoport, B., and McLachlan, S.M. (2000) Clin. Exp. Immunol. 119, 38-46[CrossRef][Medline] [Order article via Infotrieve]
  10. Dai, Y., Carayanniotis, K.A., Eliades, P., Lymberi, P., Shepherd, P., Kong, Y., and Carayanniotis, G. (1999) J. Immunol. 162, 6987-6992[Abstract/Free Full Text]
  11. Chazenbalk, G. D., Costante, G., Portolano, S., McLachlan, S. M., and Rapoport, B. (1993) J. Clin. Endocrinol. Metab. 77, 1715-1718[Abstract]
  12. Ruf, J., Toubert, M. E., Czarnocka, B., Durand-Gorde, J. M., Ferrand, M., and Carayon, P. (1989) Endocrinology 125, 1211-1218[Abstract/Free Full Text]
  13. Guo, J., Mcintosh, R.S., Czarnocka, B., Weetman, A.P., Rapoport, B., and McLachlan, S.M. (1998) Clin. Exp. Immunol. 111, 408-414[CrossRef][Medline] [Order article via Infotrieve]
  14. Gardas, A., Watson, P. F., Hobby, P., Smith, A., Weetman, A. P., Sutton, B. J., and Banga, J. P. (2000) Redox. Rep. 5, 237-241[CrossRef][Medline] [Order article via Infotrieve]
  15. Blanchin, S., Estienne, V., Guo, J., Rapoport, B., McLachlan, S.M., Carayon, P., and Ruf, J. (2002) Biochem. Biophys. Res. Commun. 295, 1118-1124[CrossRef][Medline] [Order article via Infotrieve]
  16. Arscott, P. L., Koenig, R. J., Kaplan, M. M., Glick, G. D., and Baker, J. R. (1996) J. Biol. Chem. 271, 4966-4973[Abstract/Free Full Text]
  17. Zanelli, E., Henry, M., and Malthiery, Y. (1992) Clin. Exp. Immunol. 87, 80-86[Medline] [Order article via Infotrieve]
  18. Zanelli, E., Henry, M., and Malthiery, Y. (1993) Cell. Mol. Biol. (Noisy-legrand) 39, 491-501[Medline] [Order article via Infotrieve]
  19. Grennan Jones, F., Ziemnicka, K., Sanders, J., Wolstenholme, A., Fiera, R., Furmaniak, J., and Rees Smith, B. (1999) Autoimmunity 30, 157-169[Medline] [Order article via Infotrieve]
  20. Ewins, D. L., Barnett, P. S., Tomlinson, R. W., McGregor, A. M., and Banga, J. P. (1992) Autoimmunity 11, 141-149[Medline] [Order article via Infotrieve]
  21. Estienne, V., Duthoit, C., Vinet, L., Durand-Gorde, J. M., Carayon, P., and Ruf, J. (1998) J. Biol. Chem. 273, 8056-8062[Abstract/Free Full Text]
  22. Estienne, V., Duthoit, C., Blanchin, S., Montserret, R., Durand-Gorde, J. M., Chartier, M., Baty, D., Carayon, P., and Ruf, J. (2002) Int. Immunol. 14, 359-366[Abstract/Free Full Text]
  23. Nishikawa, T., Nagayama, Y., Seto, P., and Rapoport, B. (1993) Endocrinology 133, 2496-2501[Abstract/Free Full Text]
  24. Nishikawa, T., Rapoport, B., and McLachlan, S. M. (1994) J. Clin. Endocrinol. Metab. 79, 1648-1654[Abstract]
  25. Nishikawa, T., Rapoport, B., and McLachlan, S. M. (1996) Endocrinology 137, 1000-1006[Abstract]
  26. Guo, J., Yan, X. M., McLachlan, S. M., and Rapoport, B. (2001) J. Immunol. 166, 1327-1333[Abstract/Free Full Text]
  27. Libert, F., Ludgate, M., Dinsart, C., and Vassart, G. (1991) J. Clin. Endocrinol. Metab. 73, 857-1860[Abstract/Free Full Text]
  28. Finke, R., Seto, P., and Rapoport, B. (1990) J. Clin. Endocrinol. Metab. 71, 53-59[Abstract/Free Full Text]
  29. Bresson, D., Cerutti, M., Devauchelle, G., Pugniere, M., Roquet, F., Bes, C., Bossard, C., Chardes, T., and Peraldi-Roux, S. (2003) J. Biol. Chem. 278, 9560-9569[Abstract/Free Full Text]
  30. Bresson, D., Chardes, T., Chapal, N., Bes, C., Cerutti, M., Devauchelle, G., Bouanani, M., Mani, J. C., and Peraldi-Roux, S. (2001) Hum. Antibodies 10, 109-118[Medline] [Order article via Infotrieve]
  31. Laune, D., Molina, F., Ferrieres, G., Mani, J. C., Cohen, P., Simon, D., Bernardi, T., Piechaczyk, M., Pau, B., and Granier, C. (1997) J. Biol. Chem. 272, 30937-30944[Abstract/Free Full Text]
  32. Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K., and Pease, L. R. (1989) Gene (Amst.) 77, 51-59[CrossRef][Medline] [Order article via Infotrieve]
  33. Sanger, F., Nicklen, S., and Coulson, A. R. (1977) Proc. Natl. Acad. Sci. U. S. A. 74, 5463-5467[Abstract/Free Full Text]
  34. Bes, C., Briant-Longuet, L., Cerutti, M., Heitz, F., Troadec, S., Pugniere, M., Roquet, F., Molina, F., Casset, F., Bresson, D., Peraldi-Roux, S., Devauchelle, G., Devaux, C., Granier, C., and Chardes, T. (2003) J. Biol. Chem. 278, 14265-14273[Abstract/Free Full Text]
  35. Czarnocka, B., Janota-Bzowski, M., McIntosh, R. S., Asghar, M. S., Watson, P. F., Kemp, E. H., Carayon, P., and Weetman, A. P. (1997) J. Clin. Endocrinol. Metab. 82, 2639-2644[Abstract/Free Full Text]
  36. Portolano, S., Chazenbalk, G. D., Seto, P., Hutchison, J. S., Rapoport, B., and McLachlan, S. M. (1992) J. Clin. Investig. 90, 720-726
  37. Frorath, B., Abney, C. C., Scanarini, M., Berthold, H., Hunt, N., and Northemann, W. (1992) J. Biochem. (Tokyo) 111, 633-637[Abstract/Free Full Text]
  38. Banga, J. P., Barnett, P. S., Ewins, D. L., Page, M. J., and McGregor, A. M. (1990) Autoimmunity 6, 257-268[Medline] [Order article via Infotrieve]
  39. Estienne, V., Blanchet, C., Niccoli-Sire, P., Duthoit, C., Durand-Gorde, J. M., Geourjon, C., Baty, D., Carayon, P., and Ruf, J. (1999) J. Biol. Chem. 274, 35313-35317[Abstract/Free Full Text]
  40. Guo, J., McLachlan, S. M., and Rapoport, B. (2002) J. Biol. Chem. 277, 40189-40195[Abstract/Free Full Text]
  41. Chazenbalk, G. D., Portolano, S., Russo, D., Hutchison, J. S., Rapoport, B., and McLachlan, S. M. (1993) J. Clin. Investig. 92, 62-74
  42. Zinkernagel, R.M. (2002) Ann. N. Y. Acad. Sci. 958, 3-6[Medline] [Order article via Infotrieve]
  43. von Herrath, M.G. (2000) J. Neuroimmunol. 107, 154-160[CrossRef][Medline] [Order article via Infotrieve]
  44. Flodstrom-Tullberg, M. (2003) Microb. Infect. 5, 911-921[CrossRef][Medline] [Order article via Infotrieve]
  45. Regner, M., and Lambert, P.H. (2001) Nat. Immunol. 2, 185-188[CrossRef][Medline] [Order article via Infotrieve]
  46. Christen, U., and von Herrath, M.G. (2004) Mol. Immunol. 40, 1113-1120[CrossRef][Medline] [Order article via Infotrieve]
  47. Tong, J.C., Myers, M.A., Mackay, I.R., Zimmet, P.Z., and Rowley, M.J. (2002) Ann. N. Y. Acad. Sci. 958, 182-189[Medline] [Order article via Infotrieve]
  48. Fairweather, D., Rose, N.R. (2002) Nat. Immunol. 3, 338-340[CrossRef][Medline] [Order article via Infotrieve]
  49. van den Hoogen, B.G., de Jong, J.C., Groen, J., Kuiken, T., de Groot, R., Fouchier, R.A., and Osterhaus, A.D. (2001) Nat. Med. 7, 719-724[CrossRef][Medline] [Order article via Infotrieve]
  50. McLachlan, S. M., and Rapoport, B. (2000) Int. Rev. Immunol. 19, 587-618[Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Onda, R. Beers, L. Xiang, S. Nagata, Q.-c. Wang, and I. Pastan
An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes
PNAS, August 12, 2008; 105(32): 11311 - 11316.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Deladoey, N. Pfarr, J.-M. Vuissoz, J. Parma, G. Vassart, S. Biesterfeld, J. Pohlenz, and G. Van Vliet
Pseudodominant Inheritance of Goitrous Congenital Hypothyroidism Caused by TPO Mutations: Molecular and in Silico Studies
J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 627 - 633.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Onda, S. Nagata, D. J. FitzGerald, R. Beers, R. J. Fisher, J. J. Vincent, B. Lee, M. Nakamura, J. Hwang, R. J. Kreitman, et al.
Characterization of the B Cell Epitopes Associated with a Truncated Form of Pseudomonas Exotoxin (PE38) Used to Make Immunotoxins for the Treatment of Cancer Patients
J. Immunol., December 15, 2006; 177(12): 8822 - 8834.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Dubska, J. P. Banga, D. Plochocka, G. Hoser, E. H. Kemp, B. J. Sutton, A. Gardas, and M. Gora
Structural Insights into Autoreactive Determinants in Thyroid Peroxidase Composed of Discontinuous and Multiple Key Contact Amino Acid Residues Contributing to Epitopes Recognized by Patients' Autoantibodies
Endocrinology, December 1, 2006; 147(12): 5995 - 6003.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
S. A. Rebuffat, D. Bresson, B. Nguyen, and S. Peraldi-Roux
The key residues in the immunodominant region 353-363 of human thyroid peroxidase were identified
Int. Immunol., July 1, 2006; 18(7): 1091 - 1099.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
D. Bresson, S. A. Rebuffat, B. Nguyen, J. P. Banga, A. Gardas, and S. Peraldi-Roux
New Insights into the Conformational Dominant Epitopes on Thyroid Peroxidase Recognized by Human Autoantibodies
Endocrinology, June 1, 2005; 146(6): 2834 - 2844.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/37/39058    most recent
M403897200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bresson, D.
Right arrow Articles by Péraldi-Roux, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bresson, D.
Right arrow Articles by Péraldi-Roux, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement